Journal of Okayama Medical Association
Published by Okayama Medical Association

Full-text articles are available 3 years after publication.


小倉 俊郎 岡山大学医学部第三内科学教室 Kaken ID publons researchmap
長宅 芳男 岡山大学医学部第三内科学教室
槇野 博史 岡山大学医学部第三内科学教室
原本 俊則 岡山大学医学部第三内科学教室
松本 光仁 尾道市立市民病院内科
平松 信 岡山済生会総合病院内科
味埜 泰明 落合病院内科
西村 誠明 岡山中央病院内科
谷合 一陽 岡山中央病院内科
熊谷 功 寺岡記念病院腎センター
河本 紀一 因島総合病院内科
竹久 義明 鳥取市立病院内科
松浦 梅春 姫路第一病院内科
菅 嘉彦 菅病院内科
太田 善介 岡山大学医学部第三内科学教室
106_655.pdf 330 KB
The beneficial effect of recombinant human erythropoietin (EPO) for renal anemia in patients with chronic hemodialysis has been esthablishel. EPO is reported to be effective against renal anemia when adeministered at a dose 3,000 units three times a week. However, only a few studies have been made on the therapy to maintain the anemia-improving effect of EPO. In the present study, we performed EPO maintenance therapy on 22 hemodialysis patients with renal anemia. EPO was initialy administered at a dose of 3,000 units three times a week, and maintenance therapy was initiated after 12 weeks of treatment. The patients were divided into two groups, with EPO being administered at a dose of 1,500 units twice a week to one group and three times a week to the other. The duration of maintenance therapy was set at eight weeks. The anemia-improving effect of EPO was found to be satisfactorily maintained in both groups and no significant difference was noted between them. According, it may be better to use the lower dose regimen of 1,500 units twice a week for the maintenance therapy of renal anemia.